{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-193450","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.224053+00:00","generated_at":"2026-05-17T08:56:56.769191+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coya Therapeutics receives $4.2M milestone from Dr. Reddy's for ALS IND acceptance","bullets":["FDA accepted IND for COYA 302 Phase 2 study in ALS, triggering $4.2M milestone from Dr. Reddy's Laboratories.","Additional $4.2M payment due upon first patient dosing in the Phase 2 study.","Phase 2 trial is randomized, double-blind, placebo-controlled, 24-week with 24-week open-label extension.","Milestone arises from Development and License Agreement signed December 5, 2023.","Payment signals progress in clinical development for COYA 302 combination therapy in ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-193450","json":"https://secwatch.observer/filing/0001193125-25-193450.json","markdown":"https://secwatch.observer/filing/0001193125-25-193450.md","text":"https://secwatch.observer/filing/0001193125-25-193450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525193450/0001193125-25-193450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312525193450/d95745d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:56:56.769191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}